A Phase 2, Multicenter, Randomized, Partially-Blind, Dose-Ranging Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of VX-135 and Daclatasvir in Treatment-Naive Adult Subjects With Genotype 1 Chronic Hepatitis C

Trial Profile

A Phase 2, Multicenter, Randomized, Partially-Blind, Dose-Ranging Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of VX-135 and Daclatasvir in Treatment-Naive Adult Subjects With Genotype 1 Chronic Hepatitis C

Completed
Phase of Trial: Phase II

Latest Information Update: 04 Feb 2016

At a glance

  • Drugs Daclatasvir (Primary) ; VX 135 (Primary)
  • Indications Hepatitis C
  • Focus Adverse reactions
  • Sponsors Vertex Pharmaceuticals
  • Most Recent Events

    • 04 May 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov
    • 13 Apr 2014 Results presented at the 49th Annual Meeting of the European Association for the Study of the Liver.
    • 13 Apr 2014 Interim results presented at the 49th Annual Meeting of the European Association for the Study of the Liver.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top